文献速递中毒与环境急症消化、代谢与肾脏急症

医疗保险D部分受益人同时使用阿片类药物与苯二氮䓬类药物的暴露-反应关联与阿片相关过量风险

Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries.
PubMed 文献 · JAMA Netw Open · 2018-06-01
一句话结论在同时使用阿片类和苯二氮䓬类的头90天内,阿片相关过量风险约为单用阿片类的5倍,提示需密切监测。

该回顾性队列研究利用2013年1月1日至2014年12月31日医疗保险D部分理赔数据,纳入2014年至少配取1次阿片类处方的受益人。按过量或删失前一日是否有阿片类与苯二氮䓬类供应分组,采用Cox比例风险模型比较阿片相关过量风险。结果显示,同时使用两类药物者20 665例(占71 248例的29.0%),其中68.4%重叠供应超过180天;头90天过量风险最高(HR 5.05,95%CI 3.68-6.93),91-180天为HR 1.87(95%CI 1.25-2.80)。作者认为应实施遏制同时使用两类药物的政策,并对同时使用者密切监测,尤其是初始合用阶段。

要点

  • 在同时使用阿片类和苯二氮䓬类的头90天内,阿片相关过量风险是单用阿片类的5.05倍(95%CI 3.68-6.93)。
  • 在未于头90天发生事件者中,同时使用第91-180天的过量风险为HR 1.87(95%CI 1.25-2.80)。
  • 71 248例阿片类处方患者中,20 665例(29.0%)在过量或删失前一日同时使用苯二氮䓬类,其中14 132例(68.4%)重叠供应超过180天。
  • 风险在同时使用的最初几天最高,并随时间下降。
  • 作者认为应实施遏制同时使用阿片类和苯二氮䓬类的政策,并对同时使用者密切监测,尤其是合用最初几天。

适用人群与场景

  • 2014年至少配取1次阿片类处方的医疗保险D部分受益人。
  • 研究基于2013年1月1日至2014年12月31日的医疗保险D部分理赔数据,分析于2017年秋季和2018年春季进行。

研究设计与关键结果

  • 研究类型:回顾性队列研究;数据来源:2013年1月1日至2014年12月31日医疗保险D部分理赔数据;样本量71 248例,其中男性25 600例(35.9%),白人59 532例(83.6%),平均(SD)年龄66.5(14.8)岁。
  • 分组:仅阿片类供应组n=50 583;阿片类与苯二氮䓬类同时供应组n=20 665,并进一步按重叠供应累计天数分为1-90天(n=3603)、91-180天(n=2930)、181-270天(n=4082)、271天及以上(n=10 050)。
  • 主要终点:阿片相关过量(含致死性和非致死性过量);采用Cox比例风险模型,控制人口学特征、保险因素、临床特征及阿片类和苯二氮䓬类处方者数量。
  • 与单用阿片类相比,同时使用阿片类和苯二氮䓬类头90天的过量风险HR为5.05(95%CI 3.68-6.93);在头90天未发生事件者中,第91-180天的HR为1.87(95%CI 1.25-2.80)。
  • 风险在同时使用的最初几天最高,并随时间下降。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应实施遏制同时使用阿片类和苯二氮䓬类的政策。
  • 作者认为,同时使用阿片类和苯二氮䓬类的患者应密切监测,尤其是同时使用的最初几天。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Concurrent benzodiazepine use is associated with an increased risk of opioid-related overdose; however, it remains unknown how the overdose risk varies with the days of exposure to both medications.

OBJECTIVE: To evaluate the exposure-response association between the days with concurrent prescription opioid and benzodiazepine use and the risk of overdose.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of Medicare Part D claims data from January 1, 2013, to December 31, 2014. Analyses were conducted in fall 2017 and spring 2018. Participants were Medicare Part D beneficiaries who filled at least 1 prescription for an opioid in 2014.

EXPOSURES: Patients were divided into 2 groups based on whether they had opioid and benzodiazepine supplies on the day before overdose or censoring. The first group only had a supply of opioids (n = 50 583) and the second group had supplies of opioids and benzodiazepines (n = 20 665). The second group was further categorized into 4 subgroups based on the cumulative number of days with overlapping supplies of opioids and benzodiazepines: 1 to 90 days (n = 3603), 91 to 180 days (n = 2930), 181 to 270 days (n = 4082), and 271 days or more (n = 10 050).

MAIN OUTCOMES AND MEASURES: Cox proportional hazard models were constructed to compare opioid-related overdose (including fatal and nonfatal overdoses) across time-dependent treatment groups, controlling for demographic characteristics, insurance factors, clinical characteristics, and number of unique opioid and benzodiazepine prescribers.

RESULTS: Of 71 248 total participants, 25 600 (35.9%) were male and 59 532 (83.6%) were white. Mean (SD) age was 66.5 (14.8) years. On the day before overdose or censoring event, 20 665 of 71 248 patients with an opioid prescription (29.0%) were concurrently using benzodiazepines and 14 132 of 20 665 concurrent users (68.4%) had more than 180 days of overlapping supplies of both medications. The risk of overdose was highest on the first days of concurrent opioid and benzodiazepine use and decreased over time; compared with opioid use alone, the hazard ratio for overdose was 5.05 (95% CI, 3.68-6.93) during the first 90 days of concurrent opioid and benzodiazepine use and 1.87 (95% CI, 1.25-2.80) for days 91 to 180 among those who did not have an event before 90 days.

CONCLUSIONS AND RELEVANCE: During the first 90 days, concurrent benzodiazepine use is associated with a 5-fold increase in the risk of opioid-related overdose. The implementation of policies deterring concurrent opioid and benzodiazepine use is warranted. Patients using both medications should be closely monitored, particularly during the first days of concurrent use.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hernandez I, He M, Brooks MM, et al. Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. JAMA Netw Open. 2018. PMID: 30646080. doi:10.1001/jamanetworkopen.2018.0919

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。